SARASOTA, Fla., Oct. 1, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that CEO Kelvin Cooper, Ph.D., will participate in three upcoming industry conferences.

Dr. Cooper is scheduled to attend the Maxim Growth Summit on October 14, 2026, in New York City. He will also attend and present at the ThinkEquity Conference on October 15, 2026, in New York City. Later in the month, Dr. Cooper will present a poster on Nu-3 preclinical data at IDWeek on October 22, 2026, in Washington D.C.

Details are as follows:

The conferences provide opportunities for Lakewood-Amedex to engage with members of the investment, biotechnology, and infectious disease communities and highlight the Company's ongoing development programs Bisphosphocin® antimicrobial technology.

About Lakewood-Amedex Biotherapeutics, Inc.

Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.

Contacts:

Investor Relations

Tiberend Strategic Advisors, Inc.

David Irish

(231) 632-0002

[email protected] 

Media Relations

Tiberend Strategic Advisors, Inc.

Casey McDonald

(646) 577-8520

[email protected]

Michelle Katsel

(201) 790-3390

[email protected]

SOURCE Lakewood-Amedex Biotherapeutics Inc.

Share this article